However, the relevant guidelines have not yet advocated the use of ALK TKIs for the neoadjuvant treatment of early-stage ALK-positive NSCLC patients, and there is a lack of outcome data from large, randomized trials (22). The gene discussed is ALK; the disease is non-small cell lung carcinoma.